Guardian Ion: Intravenous Magnesium as a Nephroprotective Ally in Cisplatin Therapy

Cisplatin remains the chemotherapeutic workhorse for various solid tumors, but its Achilles' heel is nephrotoxicity.Up to one in three patients experiences some degree of cisplatin-associated acute kidney injury (CP-AKI), jeopardizing future cancer therapy options and long-term kidney health (1).Against this backdrop, Gupta and colleagues deliver the largest known human study to date assessing whether a simple, inexpensive maneuver-prophylactic intravenous (iv) magnesium-can blunt CP-AKI risk (2).Their multicenter cohort analysis of 13,719 adults treated between 2006 and 2022 across five US cancer centers provides compelling real-world evidence that magnesium matters.